Tag Archives: biotechnology news

Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…

Posted on June 26, 2012 by Warren Woessner

Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

From The EPO: Oral Proceedings/Interviews Before Examining Division Can Be Held Via Videoconferencing

Posted on June 14, 2012 by Warren Woessner

This is a guest post from Lynnea Fedyk, legal process assistant at Schwegman, Lundberg & Woessner, P.A. Attached are two documents of particular interest regarding Oral Proceedings by video conference and submission of email during video conference. Should you like to … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , , | Leave a comment

USPTO Proposes Rules To Implement Micro Entity Patent Fee Provisions Of AIA

Posted on June 4, 2012 by Warren Woessner

A guest post from Gary Speier, shareholder with Schwegman, Lundberg & Woessner. Last week, the USPTO published a Federal Register notice proposing rules for implementing certain provisions of section 10 of the America Invents Act related to micro entities. (A … Continue reading →

Posted in AIA Patent Reform, Patent Reform Legislation, USPTO Rules re 2AIA Patent Reform | Tagged , , , , , , , , , | Leave a comment

Prometheus Unbound – Are Methods Of Medical Treatment The Next “Targets”?

Posted on May 22, 2012 by Warren Woessner

In my March post “Unnatural Acts – Patenting Diagnostic Tests Post-Prometheus” I wrote: “I have been trying to formulate diagnostic claims that would pass muster post-Prometheus and I am having trouble. If a researcher discovers the marker, the researcher should … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 2 Comments